Format

Send to

Choose Destination
Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Author information

1
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
2
Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
3
Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.

PMID:
26916808
DOI:
10.1002/cpt.360
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center